Case study · With CureVac SE
Reducing material costs in mRNA in vitro transcription without compromising quality
DataHow and CureVac SE explored what development effort is needed to reduce excess IVT materials while still meeting CQAs and yield for two mRNA sequences.
-
~90%
Of the cost to manufacture mRNA at scale comes from materials
-
~6
Runs were enough to adapt the model to a new mRNA sequence
-
Raw material cost for IVT reduced while holding CQA specifications and yield
The challenge
Expensive compounds used in excess
Platform IVT conditions add enzymes and capping agents at levels that meet CQAs and yield regardless of the sequence, so for many sequences these expensive compounds are added in excess.
The approach
Hybrid modeling and transfer learning
CureVac SE executed a designed set of runs. A hybrid model captured how inputs drive outcomes, transfer learning adapted it to a second sequence, and the model proposed conditions that cut material use.
- 20 experimental runs
- 2 mRNA sequences
- IVT bioprocess step
Get the full results
Download the full case study, with project outline, analysis, and case results.